The 22 references in paper A. Lidzhieva A., E. Smolyarchuk A., А. Лиджиева А., Е. Смолярчук А. (2018) “Левосальбутамол - новые возможности лечения бронхиальной астмы (обзор исследований) // Levosalbutamol and new opportunities for the treatment of bronchial asthma (review of the related studies)” / spz:neicon:vedomostincesmp:y:2015:i:2:p:25-28

1
Bronchial asthma. Global Strategy. Pulmonologiya1996; Suppl. 166 (in Russian).
(check this in PDF content)
2
Chuchalin AG. Чучалин АГ. Bronchial asthma. Мoscow: Agar; 1997 (in Russian).
(check this in PDF content)
3
Jonson M. β2-adrenoceptor agonists: optimal pharmacological profile. In: The role of b2-agonists in asthma management. Oxford: The Medicine Group; 1993.
(check this in PDF content)
4
Avdeev SN. Inhaled drug delivery device used in the therapy of airway diseases. Rossiyskiy meditsinskiy zhurnal 2002; (5): 255–261 (in Russian).
(check this in PDF content)
5
Dhand R, Goode M, Reid R, et al. Preferential pulmonary retention of (S) – albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med. 1999; 160: 1136–41.
(check this in PDF content)
6
Prior JG, Cochrane GM, Raper SM, Ali C, Volans GN. Self-poisoning with oral salbutamol. BMJ 1981; 282: 1932.
(check this in PDF content)
7
Handley D. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists. J Allergy Clin Immunol. 1999; 104: S69–S76.
(check this in PDF content)
8
Drugs@FDA. FDA Approved Drug Products. Available from: http:// www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
(check this in PDF content)
9
National Institutes of Health, National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; April 1997. NIH publication 97–4051.
(check this in PDF content)
10
Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996; 14: 37–45. R E F E R E N C E S Research Institute of Pharmacy of I.M. Sechenov First Moscow State Medical University, 45, Nahimovsky avenue, Moscow, 119991, Russian Federation. Lidzhieva AA. Graduate student. Smolyarchuk EA. Head of Department of new medicines introduction. Candidate of Medical Sciences. Научно-исследовательский институт фармации Первого Московского государственного медицинского университета им. И.М. Сеченова. Российская Федерация, 117418, Москва, Нахимовский проспект, 45. Лиджиева Алевтина Анатольевна. Аспирант. Смолярчук Елена Анатольевна. Заведующая
(check this in PDF content)
11
Johansson F, Rydberg I, Aberg G, et al. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996; 14: 57–64.
(check this in PDF content)
12
Matthew J. Randall, Shannon F. Kostin, Edward J. Burgess, Laura R. Hoyt, Jennifer L. Ather, Lennart K. Lundblad, Matthew E. Poynter. Anti-Inflammatory Effects of Levalbuterol-Induced 11β-Hydroxysteroid Dehydrogenase Type 1 Activity in Airway Epithelial Cells. Front Endocrinol. 2015 Jan 12; (5): 236.
(check this in PDF content)
13
Raffay T, Ko P, Reynolds J, Di Fiore J, MacFarlane P, Martin RJ. Repeated β2adrenergic receptor agonist therapy attenuates the response to rescue bronchodilation in a hyperoxic newborn mouse model. Neonatology 2014; 106(2): 126–32
(check this in PDF content)
14
Johansson F, Rydberg I, Aberg G, et al. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol. 1996; 14: 57–64.
(check this in PDF content)
15
Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol. 1996; 14: 37–45.
(check this in PDF content)
16
Morley J. Anomalous effects of albuterol and other sympathomimetics in the guinea pig. Clin Rev Allergy Immunol. 1996; 14: 65–89.
(check this in PDF content)
17
Lipworth BJ, Clark DJ, Koch P, Arbeeny C. Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997; 52: 849–52.
(check this in PDF content)
18
Carl J, Myers T, Kercsmar C. Comparison of levalbuterol and racemic albuterol for treatment of acute asthma in pediatric patients [abstract]. Chest 2001; 120(suppl): 137S.
(check this in PDF content)
19
Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998; 102: 943–52.
(check this in PDF content)
20
Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetics and pharmacodynamics of cumulative single dose of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther. 1999; 12(6): 353–62.
(check this in PDF content)
21
Jan Lötvall, Mona Palmqvist, Peter Arvidsson, Alan Maloney, Pietro Ventresca, Jonathan Ward. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. Göteborg, Sweden, and Greenford, United Kingdom. July 27, 2001; S-413 45 Gothenburg, Sweden.
(check this in PDF content)
22
Kavita Rathore, Tarun Kumar Sharma, ML Aseri, Sunil Kumar Mathur, Rakesh Chandra Gupta, Satish Kumar Vardey, GG Kaushik, Maheep Sinha. Comparative study of pulmonary functions after administration of albuterol and levalbuterol in patients with moderate to severe bronchial asthma. International Journal of Medicine and Medical Sciences 2012; 4(2): 39–44.
(check this in PDF content)